

Revision Date 19-Sep-2024 Revision Number 6

# SECTION 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

**Product Description:** EliA Thyroid Positive Control 200

Cat No.: 83-1160-01

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use In vitro diagnostic
Uses advised against All other uses

1.3. Details of the supplier of the safety data sheet

**Company** Phadia AB

Rapsgatan 7P P.O. Box 6460 751 37 UPPSALA

Sweden

+46 18 16 50 00

E-mail address safetydatasheet.idd@thermofisher.com

1.4. Emergency telephone number

CHEMTREC Ireland (Dublin) +(353)-19014670 CHEMTREC Belgium (Brussels) +(32)-28083237

Malta 112 Emergency phone number

## **SECTION 2: HAZARDS IDENTIFICATION**

#### 2.1. Classification of the substance or mixture

#### GHS Classification - According to GB-CLP Regulations UK SI 2019/720 and UK SI 2020/1567

#### Physical hazards

Based on available data, the classification criteria are not met

#### **Health hazards**

Based on available data, the classification criteria are not met

#### **Environmental hazards**

Based on available data, the classification criteria are not met

For the full text of the H-statements mentioned in this Section, see Section 16.

#### 2.2. Label elements

None

#### 2.3. Other hazards

This material is prepared from a human source base. Donors have been tested by FDA approved methods and found negative for antibodies to HIV-1 and HIV-2, non-reactive for HBsAg, and non-reactive for HCV. Handle as potentially infectious material This product does not contain any known or suspected endocrine disruptors.

This preparation contains no substance considered to be persistent, bioaccumulating nor toxic (PBT). This preparation contains no substance considered to be very persistent nor very bioaccumulating (vPvB).

## **SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS**

| Component    | CAS No     | EC No             | Weight % | GHS Classification -<br>According to GB-CLP<br>Regulations UK SI<br>2019/720 and UK SI<br>2020/1567 |
|--------------|------------|-------------------|----------|---|
| Tartrazine   | 1934-21-0  | EEC No. 217-699-5 | <1       | -   |
| Sodium azide | 26628-22-8 | EEC No. 247-852-1 | <0.1     | Acute Tox. 2 (H300)<br>(EUH032)<br>Aquatic Acute 1 (H400)<br>Aquatic Chronic 1 (H410)               |

| Component    | Specific concentration limits (SCL's) | M-Factor | Component notes |
|--------------|---------------------------------------|----------|-----------------|
| Sodium azide | -                                     | 1        | -               |

For the full text of the H-statements mentioned in this Section, see Section 16.

## **SECTION 4: FIRST AID MEASURES**

#### 4.1. Description of first aid measures

**Eye Contact** Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes. If

eye irritation persists: Get medical advice/attention.

Skin Contact Wash off immediately with soap and plenty of water. Wash contaminated clothing before

reuse

Ingestion Clean mouth with water and drink afterwards plenty of water. Consult a physician if

necessary.

**Inhalation** Not an expected route of exposure.

Self-Protection of the First Aider Ensure that medical personnel are aware of the material(s) involved, take precautions to

protect themselves and prevent spread of contamination.

#### 4.2. Most important symptoms and effects, both acute and delayed

None reasonably foreseeable.

#### 4.3. Indication of any immediate medical attention and special treatment needed

**Notes to Physician** 

Treat symptomatically.

## **SECTION 5: FIREFIGHTING MEASURES**

#### 5.1. Extinguishing media

#### **Suitable Extinguishing Media**

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

#### Extinguishing media which must not be used for safety reasons

No information available.

## 5.2. Special hazards arising from the substance or mixture

None known.

#### **Hazardous Combustion Products**

None under normal use conditions.

#### 5.3. Advice for firefighters

No information available.

## **SECTION 6: ACCIDENTAL RELEASE MEASURES**

## 6.1. Personal precautions, protective equipment and emergency procedures

Wear protective gloves/clothing and eye/face protection.

#### 6.2. Environmental precautions

Dispose of in accordance with local regulations.

#### 6.3. Methods and material for containment and cleaning up

Wipe up with adsorbent material (e.g. cloth, fleece). Clean with disinfectants. Dispose of waste product or used containers according to local regulations.

#### 6.4. Reference to other sections

Refer to protective measures listed in Sections 8 and 13.

## **SECTION 7: HANDLING AND STORAGE**

## 7.1. Precautions for safe handling

Wash hands before breaks and immediately after handling the product. Do not eat, drink or smoke when using this product.

## 7.2. Conditions for safe storage, including any incompatibilities

Keep at temperatures between 2 and 8°C.

#### 7.3. Specific end use(s)

Observe instructions for use.

# **SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION**

## 8.1. Control parameters

## **Exposure limits**

List source(s): **EU** - Commission Directive (EU) 2019/1831 of 24 October 2019 establishing a fifth list of indicative occupational exposure limit values pursuant to Council Directive 98/24/EC and amending Commission Directive 2000/39/EC

| Component                 | European Union                    | The United Kingdom                       | France  | Belgium  | Spain                                      |
|---------------------------|-----------------------------------|--|---|--|--|
| Sodium azide              | TWA: 0.1 mg/m <sup>3</sup> (8h)   | STEL: 0.3 mg/m3 15 min                   | TWA / VME: 0.1 mg/m <sup>3</sup>              | TWA: 0.1 mg/m <sup>3</sup> 8 uren                        | STEL / VLA-EC: 0.3                         |
|                           | STEL: 0.3 mg/m <sup>3</sup>       | TWA: 0.1 mg/m <sup>3</sup> 8 hr          | (8 heures). restrictive                       | Huid   | mg/m <sup>3</sup> (15 minutos).            |
|                           | (15min)                           | Skin                                     | limit   |  | TWA / VLA-ED: 0.1                          |
|                           | Skin                              |  | STEL / VLCT: 0.3                              |  | mg/m³ (8 horas)                            |
|                           |                                   |  | mg/m <sup>3</sup> . restrictive limit         |  | Piel                                       |
|                           |                                   |  | Peau  |  |  |
| Component                 | Italy                             | Cormony                                  | Dertugal                                      | The Netherlands  | Finland                                    |
| Component<br>Sodium azide | TWA: 0.1 mg/m <sup>3</sup> 8 ore. | Germany<br>TWA: 0.2 mg/m <sup>3</sup> (8 | Portugal<br>STEL: 0.3 mg/m <sup>3</sup> 15    | huid   |  |
| Sodium azide              | Time Weighted Average             |  | minutos                                       | STEL: 0.3 mg/m <sup>3</sup> 15                           | TWA: 0.1 mg/m <sup>3</sup> 8<br>tunteina   |
|                           | STEL: 0.3 mg/m <sup>3</sup> 15    | exposure factor 2                        | Ceiling: 0.29 mg/m <sup>3</sup>               | minuten  | STEL: 0.3 mg/m <sup>3</sup> 15             |
|                           | minuti. Short-term                | TWA: 0.2 mg/m <sup>3</sup> (8            | Ceiling: 0.29 mg/m                            | TWA: 0.1 mg/m <sup>3</sup> 8 uren                        | minuutteina                                |
|                           | Pelle                             | Stunden). MAK                            | TWA: 0.1 mg/m <sup>3</sup> 8 horas            |  | lho  |
|                           | . 55                              | Höhepunkt: 0.4 mg/m <sup>3</sup>         | Pele  |  |  |
|                           |                                   |  |   |  |  |
| Component                 | Austria                           | Denmark                                  | Switzerland                                   | Poland   | Norway                                     |
| Sodium azide              | Haut                              | TWA: 0.1 mg/m <sup>3</sup> 8 timer       | STEL: 0.4 mg/m <sup>3</sup> 15                | STEL: 0.3 mg/m <sup>3</sup> 15                           | TWA: 0.1 mg/m <sup>3</sup> 8 time          |
|                           | MAK-KZGW: 0.3 mg/m <sup>3</sup>   | STEL: 0.3 mg/m <sup>3</sup> 15           | Minuten                                       | minutach   | STEL: 0.3 mg/m <sup>3</sup> 15             |
|                           | 15 Minuten                        | minutter                                 | TWA: 0.2 mg/m <sup>3</sup> 8                  | TWA: 0.1 mg/m <sup>3</sup> 8                             | minutter. value from the                   |
|                           | MAK-TMW: 0.1 mg/m <sup>3</sup> 8  | Hud                                      | Stunden                                       | godzinach  | regulation                                 |
|                           | Stunden                           |  |   |  |  |
| Component                 | Bulgaria                          | Croatia                                  | Ireland                                       | Cyprus   | Czech Republic                             |
| Sodium azide              | TWA: 0.1 mg/m <sup>3</sup>        | kože                                     | TWA: 0.1 mg/m <sup>3</sup> 8 hr.              | Skin-potential for                                       | TWA: 0.1 mg/m <sup>3</sup> 8               |
|                           | STEL: 0.3 mg/m <sup>3</sup>       | TWA-GVI: 0.1 mg/m <sup>3</sup> 8         | STEL: 0.3 mg/m3 15 min                        | cutaneous absorption                                     | hodinách.                                  |
|                           | Skin notation                     | satima.                                  | Skin  | STEL: 0.3 mg/m <sup>3</sup>                              | Potential for cutaneous                    |
|                           |                                   | STEL-KGVI: 0.3 mg/m <sup>3</sup>         |   | TWA: 0.1 mg/m <sup>3</sup>                               | absorption                                 |
|                           |                                   | 15 minutama.                             |   |  | Ceiling: 0.3 mg/m <sup>3</sup>             |
| Component                 | Estonia                           | Gibraltar                                | Greece  | Hungary  | Iceland                                    |
| Sodium azide              | Nahk                              | Skin notation                            | STEL: 0.1 ppm                                 | Hungary<br>STEL: 0.3 mg/m <sup>3</sup> 15                | STEL: 0.3 mg/m <sup>3</sup>                |
| Soulum azide              | TWA: 0.1 mg/m <sup>3</sup> 8      | TWA: 0.1 mg/m <sup>3</sup> 8 hr          | STEL: 0.1 ppin<br>STEL: 0.3 mg/m <sup>3</sup> | percekben. CK  | TWA: 0.1 mg/m <sup>3</sup> 8               |
|                           | tundides.                         | STEL: 0.3 mg/m <sup>3</sup> 15 min       |   | TWA: 0.1 mg/m <sup>3</sup> 8                             | klukkustundum.                             |
|                           | STEL: 0.3 mg/m <sup>3</sup> 15    |  | TWA: 0.3 mg/m <sup>3</sup>                    | órában. AK   | Skin notation                              |
|                           | minutites.                        |  |   | 0.000  |  |
|                           |                                   |  |   |  |  |
|                           |                                   |  |   |  |  |
| Component                 | Latvia                            | Lithuania                                | Luxembourg                                    | Malta  | Romania                                    |
| Component<br>Sodium azide | Latvia<br>skin - potential for    | Lithuania<br>TWA: 0.1 mg/m³ IPRD         | Possibility of significant                    | Malta possibility of significant uptake through the skin | Romania Skin notation TWA: 0.1 mg/m³ 8 ore |

| Component    | Latvia  | Lithuania                                     | Luxembourg  | Malta   | Romania |
|--------------|---|---|---|---|---------|
| Sodium azide | skin - potential for<br>cutaneous exposure<br>STEL: 0.3 mg/m³<br>TWA: 0.1 mg/m³ | TWA: 0.1 mg/m³ IPRD<br>Oda<br>STEL: 0.3 mg/m³ | Possibility of significant<br>uptake through the skin<br>TWA: 0.1 mg/m³ 8<br>Stunden<br>STEL: 0.3 mg/m³ 15<br>Minuten | possibility of significant<br>uptake through the skin<br>TWA: 0.1 mg/m³<br>STEL: 0.3 mg/m³ 15<br>minuti |         |

| Component    | Russia                   | Slovak Republic                | Slovenia                          | Sweden                       | Turkey                            |
|--------------|--------------------------|--------------------------------|-----------------------------------|------------------------------|-----------------------------------|
| Tartrazine   | MAC: 5 mg/m <sup>3</sup> |                                |                                   |                              |                                   |
| Sodium azide |                          | Ceiling: 0.3 mg/m <sup>3</sup> | TWA: 0.1 mg/m <sup>3</sup> 8 urah | Binding STEL: 0.3            | Deri                              |
|              |                          | Potential for cutaneous        | Koža                              | mg/m <sup>3</sup> 15 minuter | TWA: 0.1 mg/m <sup>3</sup> 8 saat |
|              |                          | absorption                     | STEL: 0.3 mg/m <sup>3</sup> 15    | TLV: 0.1 mg/m <sup>3</sup> 8 | STEL: 0.3 mg/m <sup>3</sup> 15    |
|              |                          | TWA: 0.1 mg/m <sup>3</sup>     | minutah                           | timmar. NGV                  | dakika                            |

## **Biological limit values**

#### **EliA Thyroid Positive Control 200**

Revision Date 19-Sep-2024

This product, as supplied, does not contain any hazardous materials with biological limits established by the region specific regulatory bodies

## **Monitoring methods**

BS EN 14042:2003 Title Identifier: Workplace atmospheres. Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents.

## Derived Minimum Effect Level (DMEL) / Derived No Effect Level (DNEL)

See table for values

| Component                           | Acute effects local (Dermal) | Acute effects systemic (Dermal) | Chronic effects local (Dermal) | Chronic effects systemic (Dermal) |
|-------------------------------------|------------------------------|---------------------------------|--------------------------------|-----------------------------------|
| Tartrazine<br>1934-21-0 ( <1 )      | (Berman)                     | systemic (Dermai)               | (Berman)                       | DNEL = 52.82mg/kg<br>bw/day       |
| Sodium azide<br>26628-22-8 ( <0.1 ) |                              |                                 |                                | DNEL = 46.7µg/kg<br>bw/day        |

| Component                           | Acute effects local (Inhalation) | Acute effects systemic (Inhalation) | Chronic effects local (Inhalation) | Chronic effects systemic (Inhalation) |
|-------------------------------------|----------------------------------|-------------------------------------|------------------------------------|---------------------------------------|
| Tartrazine<br>1934-21-0 ( <1 )      |                                  |                                     |                                    | DNEL = 372.52mg/m <sup>3</sup>        |
| Sodium azide<br>26628-22-8 ( <0.1 ) |                                  |                                     |                                    | DNEL = 0.164mg/m <sup>3</sup>         |

## **Predicted No Effect Concentration (PNEC)**

See values below.

| Component                        | Fresh water     | Fresh water sediment                  |                | Microorganisms in<br>sewage treatment | , ,                               |
|----------------------------------|-----------------|---------------------------------------|----------------|---------------------------------------|-----------------------------------|
| Tartrazine<br>1934-21-0 ( <1 )   | PNEC = 0.12mg/L | PNEC =<br>0.46992mg/kg<br>sediment dw | PNEC = 1.2mg/L | PNEC = 10mg/L                         | PNEC =<br>0.02353mg/kg soil<br>dw |
| Sodium azide 26628-22-8 ( <0.1 ) | PNEC = 0.35μg/L | PNEC = 16.7µg/kg<br>sediment dw       | PNEC = 3.5µg/L | PNEC = 30µg/L                         |                                   |

|   | Component            | Marine water     | Marine water           | Marine water   | Food chain | Air |
|---|----------------------|------------------|------------------------|----------------|------------|-----|
|   |                      |                  | sediment               | intermittent   |            |     |
|   | Tartrazine           | PNEC = 0.012mg/L | PNEC =                 |                |            |     |
|   | 1934-21-0 ( <1 )     |                  | 0.046992mg/kg          |                |            |     |
|   |                      |                  | sediment dw            |                |            |     |
| Г | Sodium azide         | PNEC = 15ng/L    | $PNEC = 0.72 \mu g/kg$ | PNEC = 150ng/L |            |     |
|   | 26628-22-8 ( < 0.1 ) | _                | sediment dw            | -              |            |     |

## 8.2. Exposure controls

## **Engineering Measures**

None under normal use conditions.

Personal protective equipment

**Eye Protection** No special protective equipment required.

Hand Protection Protective gloves.

#### **EliA Thyroid Positive Control 200**

Revision Date 19-Sep-2024

Glove material Breakthrough time Glove thickness **EU** standard Glove comments Nitrile rubber See manufacturers **FN 374** (minimum requirement)

recommendations

Skin and body protection No special protective equipment required.

**Respiratory Protection** No special protective equipment required.

No special protective equipment required Large scale/emergency use

Recommended Filter type:

No personal respiratory protective equipment normally required. Small scale/Laboratory use

Recommended half mask:-

Handle in accordance with good industrial hygiene and safety practice. **Hygiene Measures** 

Dispose of contents/containers in accordance with local regulations. **Environmental exposure controls** 

## **SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES**

#### 9.1. Information on basic physical and chemical properties

**Physical State** Liquid

**Appearance** Clear Yellow None Odor

**Odor Threshold** Not applicable

**Melting Point/Range** 0°C

**Softening Point** No data available

**Boiling Point/Range** 100°C

Flammability (liquid) No data available Flammability (solid,gas) Not applicable Not applicable **Explosion Limits** 

**Flash Point** Method - No information available Not applicable

Not applicable **Autoignition Temperature** 

No information available **Decomposition Temperature** 

7.0 - 7.3рΗ

No information available **Viscosity** 

Water Solubility Soluble in water

Solubility in other solvents No information available

Partition Coefficient (n-octanol/water)

Component log Pow -1.572 **Tartrazine** Sodium azide 0.3

**Vapor Pressure** No information available **Density / Specific Gravity** No information available

**Bulk Density** Not applicable

**Vapor Density** No information available No information available

Particle characteristics Not applicable (liquid)

9.2. Other information

**Explosive Properties** Not applicable **Oxidizing Properties** Not applicable

**Evaporation Rate** Not applicable - Not Available

## **SECTION 10: STABILITY AND REACTIVITY**

10.1. Reactivity

There are no known reactivity hazards associated with this product.

10.2. Chemical stability

Stable under normal conditions.

10.3. Possibility of hazardous reactions

**Hazardous Polymerization** Hazardous polymerization does not occur.

None under normal processing. **Hazardous Reactions** 

10.4. Conditions to avoid

None known.

10.5. Incompatible materials

None known.

10.6. Hazardous decomposition products

None under normal use conditions.

## **SECTION 11: TOXICOLOGICAL INFORMATION**

#### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

**Product Information** Product does not present an acute toxicity hazard based on known or supplied information.

(a) acute toxicity;

Oral No data available. **Dermal** No data available. Inhalation No data available.

| Component    | LD50 Oral               | LD50 Dermal         | LC50 Inhalation |
|--------------|-------------------------|---------------------|-----------------|
| Tartrazine   | LD50 > 2000 mg/kg (Rat) |                     |                 |
| Sodium azide | LD50 = 27 mg/kg (Rat)   | 20 mg/kg ( Rabbit ) | 37 mg/l ( Rat ) |

No data available. (b) skin corrosion/irritation;

No data available. (c) serious eye damage/irritation;

(d) respiratory or skin sensitization;

No data available. Respiratory No data available. Skin No data available. (e) germ cell mutagenicity;

(f) carcinogenicity; There are no known carcinogenic chemicals in this product.

| Component    | Test method | Test species / Duration | Study result                      |
|--------------|-------------|-------------------------|-----------------------------------|
| Sodium azide |             |                         | No ingredient of this product     |
|              |             |                         | present at levels greater than or |
|              |             |                         | equal to 0.1% is identified as    |
|              |             |                         | probable, possible or confirmed   |
|              |             |                         | human carcinogen by IARC.         |

**EliA Thyroid Positive Control 200** 

Revision Date 19-Sep-2024

(g) reproductive toxicity; No data available.

No data available. (h) STOT-single exposure;

(i) STOT-repeated exposure: No data available.

No data available. (j) aspiration hazard;

| Component    | Other Adverse Effects  |
|--------------|--|
| Sodium azide | Symptoms of overexposure are dizziness, headache, tiredness, |
|              | nausea, unconsciousness, cessation of breathing. Harmful to  |
|              | central nervous system and heart. Fatal if swallowed.        |

Symptoms / effects,both acute and delayed No information available.

#### 11.2. Information on other hazards

**Endocrine Disrupting Properties** This product does not contain any known or suspected endocrine disruptors.

## **SECTION 12: ECOLOGICAL INFORMATION**

#### 12.1. Toxicity

No information available. **Ecotoxicity effects** 

| Component    | Freshwater Fish      | Water Flea           | Freshwater Algae      | Microtox         |
|--------------|----------------------|----------------------|-----------------------|------------------|
| Sodium azide | LC50 96 h 0.7 mg/L   | EC50 4.2 mg/l 48 h ( |                       | EC50 38.5 mg/l ( |
|              | LC50 96 h            | Daphnia pulex )      | IC50 272 mg/l ( green | Photobacterium   |
|              | LC50 0.7 mg/l 96 H ( |                      | algae)                | phosphoreum)     |
|              | Lepomis macrochirus) |                      |                       |                  |

## **12.2. Persistence and degradability** No information available.

#### No information available. 12.3. Bioaccumulative potential

| Component    | log Pow | Bioconcentration factor (BCF) |
|--------------|---------|-------------------------------|
| Tartrazine   | -1.572  |                               |
| Sodium azide | 0.3     |                               |

12.4. Mobility in soil No information available.

12.5. Results of PBT and vPvB

<u>assessment</u>

This preparation contains no substance considered to be persistent, bioaccumulating nor toxic (PBT). This preparation contains no substance considered to be very persistent nor

very bioaccumulating (vPvB).

12.6. Endocrine disrupting

properties

**Endocrine Disruptor Information** This product does not contain any known or suspected endocrine disruptors

12.7. Other adverse effects

**Persistent Organic Pollutant Ozone Depletion Potential** 

This product does not contain any known or suspected substance. This product does not contain any known or suspected substance.

## **SECTION 13: DISPOSAL CONSIDERATIONS**

13.1. Waste treatment methods

Waste from Residues/Unused

**Products** 

Dispose of in accordance with local regulations.

**Contaminated Packaging** Dispose of in accordance with local regulations.

**European Waste Catalogue (EWC)** 

18 01 07 Chemicals other than those mentioned in 18 01 06.

Other Information No information available.

## **SECTION 14: TRANSPORT INFORMATION**

IMDG/IMO Not regulated

14.1. UN number

14.2. UN proper shipping name

14.3. Transport hazard class(es)

14.4. Packing group

ADR Not regulated

14.1. UN number

14.2. UN proper shipping name

14.3. Transport hazard class(es)

14.4. Packing group

<u>IATA</u> Not regulated

14.1. UN number

14.2. UN proper shipping name

14.3. Transport hazard class(es)

14.4. Packing group

**14.5. Environmental hazards** No hazards identified.

**14.6. Special precautions for user** No special precautions required.

14.7. Maritime transport in bulk

according to IMO instruments

**SECTION 15: REGULATORY INFORMATION** 

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Not applicable, packaged goods.

International Inventories X = listed

| Component    | EINECS    | ELINCS | NLP | TSCA | DSL | NDSL | PICCS | ENCS | IECSC | AICS | KECL    |
|--------------|-----------|--------|-----|------|-----|------|-------|------|-------|------|---------|
| Tartrazine   | 217-699-5 | -      |     | Х    | Х   | -    | Χ     | Х    | Х     | Х    | KE-0685 |
|              |           |        |     |      |     |      |       |      |       |      | 7       |
| Sodium azide | 247-852-1 | -      |     | Х    | Χ   | -    | Χ     | Χ    | Χ     | Χ    | KE-3135 |
|              |           |        |     |      |     |      |       |      |       |      | 7       |

| Component  | <br>REACH (1907/2006) - Annex XVII -<br>Restrictions on Certain Dangerous<br>Substances |  |
|------------|---|--|
| Tartrazine | Use restricted. See entry 75.   |  |

#### **EliA Thyroid Positive Control 200**

Revision Date 19-Sep-2024

|              | (see link for restriction details)             |   |  |  |
|--------------|--|---|--|--|
|              |  |   |  |  |
| Component    | Seveso III Directive (2012/18/EC) - Qualifying | Seveso III Directive (2012/18/EC) - Qualifying Quantities |  |  |
| -            | Quantities for Major Accident Notification     | for Safety Report Requirements                            |  |  |
| Sodium azide | H2 50-200 ton. E1 100-200 ton                  | H2 50-200 ton, E1 100-200 ton                             |  |  |

(see link for restriction details)

Regulation (EC) No 649/2012 of the European Parliament and of the Council of 4 July 2012 concerning the export and import of dangerous chemicals

Not applicable

#### **National Regulations**

| Component    | Germany - Water Classification (AwSV) | Germany - TA-Luft Class |
|--------------|---------------------------------------|-------------------------|
| Tartrazine   | WGK1                                  |                         |
| Sodium azide | WGK2                                  |                         |

UK - Take note of Control of Substances Hazardous to Health Regulations (COSHH) 2002 and 2005 Amendment. Take note of Directive 2000/39/EC establishing a first list of indicative occupational exposure limit values .

#### 15.2. Chemical safety assessment

A Chemical Safety Assessment/Report (CSA/CSR) is not required.

## **SECTION 16: OTHER INFORMATION**

#### Full text of H-Statements referred to under sections 2 and 3

H300 - Fatal if swallowed

H400 - Very toxic to aquatic life

H410 - Very toxic to aquatic life with long lasting effects

EUH032 - Contact with acids liberates very toxic gas

## Legend

CAS - Chemical Abstracts Service

TSCA - United States Toxic Substances Control Act Section 8(b)

EINECS/ELINCS - European Inventory of Existing Commercial Chemical DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances/EU List of Notified Chemical Substances

PICCS - Philippines Inventory of Chemicals and Chemical Substances

**IECSC** - Chinese Inventory of Existing Chemical Substances

**KECL** - Korean Existing and Evaluated Chemical Substances

Inventory

Substances List **ENCS** - Japanese Existing and New Chemical Substances

AICS - Australian Inventory of Chemical Substances

NZIoC - New Zealand Inventory of Chemicals

WEL - Workplace Exposure Limit

**ACGIH** - American Conference of Governmental Industrial Hygienists

**DNEL** - Derived No Effect Level

RPE - Respiratory Protective Equipment

LC50 - Lethal Concentration 50%

NOEC - No Observed Effect Concentration

PBT - Persistent, Bioaccumulative, Toxic

TWA - Time Weighted Average

IARC - International Agency for Research on Cancer

Predicted No Effect Concentration (PNEC)

LD50 - Lethal Dose 50%

EC50 - Effective Concentration 50%

POW - Partition coefficient Octanol:Water

vPvB - very Persistent, very Bioaccumulative

ADR - European Agreement Concerning the International Carriage of Dangerous Goods by Road

IMO/IMDG - International Maritime Organization/International Maritime Dangerous Goods Code

**OECD** - Organisation for Economic Co-operation and Development

**BCF** - Bioconcentration factor

ICAO/IATA - International Civil Aviation Organization/International Air Transport Association

MARPOL - International Convention for the Prevention of Pollution from Ships

ATE - Acute Toxicity Estimate VOC (volatile organic compound)

#### Key literature references and sources for data

https://echa.europa.eu/information-on-chemicals

Suppliers safety data sheet, Chemadvisor - LOLI, Merck index, RTECS

#### **Training Advice**

Chemical hazard awareness training, incorporating labelling, Safety Data Sheets (SDS), Personal Protective Equipment (PPE) and

**EliA Thyroid Positive Control 200** 

Revision Date 19-Sep-2024

hygiene.

Revision Date 19-Sep-2024

**Revision Summary** SDS sections updated, 3, 7.

# This safety data sheet complies with Regulation UK SI 2019/758 and UK SI 2020/1577 as amended

#### **Disclaimer**

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text

## **End of Safety Data Sheet**